Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy

作者：Nakamura Kazuhiko^*; Ihara Eikichi; Akiho Hirotada; Akahoshi Kazuya; Harada Naohiko; Ochiai Toshiaki; Nakamura Norimoto; Ogino Haruei; Iwasa Tsutomu; Aso Akira; Iboshi Yoichiro; Takayanagi Ryoichi

来源：Gut and Liver, 2016, 10(6): 917-924.

DOI：10.5009/gnl15486

• Stomach ulcer
• Therapeutics
• Endoscopy
• Antiulcer agents
• Proton pump inhibitors

Background/Aims: The ability of endoscopic submucosal dissection (ESD) to resect large early gastric cancers (EGCs) results in the need to treat large artificial gastric ulcers. This study assessed whether the combination therapy of rebamipide plus a proton pump inhibitor (PPI) offered benefits over PPI monotherapy. Methods: In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66). The Scar stage (S stage) ratio after treatment was compared, and factors independently associated with ulcer healing were identified by using multivariate analyses. Results: The S stage rates at 4 and 8 weeks were similar in the two groups, even in the subgroups of patients with large amounts of tissue resected and regardless of CYP2C19 genotype. Independent factors for ulcer healing were circumferential location of the tumor and resected tissue size; the type of treatment did not affect ulcer healing. Conclusions: Combination therapy with rebamipide and PPI had limited benefits compared with PPI monotherapy in the treatment of post-ESD gastric ulcer CUMIN Clinical Trials Registry, UMIN000007435).

• 出版日期2016-11